Startpage News
Startpage

News

1
MAR
2019

Latvian Biomedical Research and Studies Centre launches new project "Identification of clinical subgroups of Type 2 diabetes mellitus and application of pharmacogenetics in development of personalized antidiabetic therapy”


Latvian Biomedical Research and Studies Centre launches new project "Identification of clinical subgroups of Type 2 diabetes mellitus and application of pharmacogenetics in development of personalized antidiabetic therapy”

 

 

On 1st March BMC will be launched European Regional Development Fund (ERDF) “On Implementation of Activity 1.1.1.2 “Post-doctoral Research Aid” of the Specific Aid Objective 1.1.1 “To increase the research and innovative capacity of scientific institutions of Latvia and the ability to attract external financing, investing in human resources and infrastructure” of the Operational Programme “Growth and Employment”

“Identification of clinical subgroups of Type 2 diabetes mellitus and application of pharmacogenetics in development of personalized antidiabetic therapy” (Project Identification No 1.1.1.2/VIAA/2/18/287). The project principle investigator is Dr. biol. Linda Zaharenko.

About the project: 

The aim of the project is use state-of-art genetic and analysis methods to stratify T2DM patients according to their risk of developing complications and genetic markers to predict patient-centred therapy outcomes and optimal therapy choices.

Quick links



Mājas lapas izstrādi finansēja ERAF 2.1.1.2. aktivitātes projekts Nr. 2010/0196/2DP/2.1.1.2.0/10/APIA/VIAA/004 "Latvijas biomedicīnas pētījumu integrācija Eiropas zinātnes telpā".